Abivax Board of Directors Update: A New Chapter Begins
Abivax SA (NASDAQ: ABVX) has recently announced significant changes within its Board of Directors. This adjustment comes on the heels of Dr. Philippe Pouletty's resignation from his director role, effective at the end of the year. His departure marks a pivotal transition for the company, one rooted in his dedication to advancing innovative treatments for chronic inflammatory diseases.
A Legacy of Leadership
Dr. Philippe Pouletty, a key figure in the establishment of Abivax, has been instrumental in its development since its founding in December 2013. As the former Chairman of the Board, he played a vital role in guiding the company through its formative years and beyond. His resignation aligns with his recent appointment as Chairman and CEO of a biotechnology firm focused on the plastics recycling sector.
Company Commitment to Patients
Philippe Pouletty expressed deep pride in his journey with Abivax and emphasized the company’s dedication to addressing severe inflammatory diseases through innovation. He confidently stated that under capable leadership, Abivax is well-positioned to impact many patients’ lives. This sentiment reflects the company’s ongoing mission to harness the body's natural mechanisms to regulate inflammation effectively.
Board Recognizes Contributions
Sylvie Grégoire, PharmD, the current Chair of the Board, acknowledged Dr. Pouletty’s significant contributions during his time with Abivax. She thanked him for his commitment and leadership, particularly in the advancement of their lead drug candidate, obefazimod, which is now in Phase 3 clinical trials for ulcerative colitis.
Looking Ahead
Abivax is committed to filling the vacancy left by Dr. Pouletty with a candidate who brings expertise and vision to further propel the company’s late-stage pipeline in inflammatory bowel disease (IBD).
About Abivax
Abivax is a distinct entity within the biotechnology landscape, primarily focused on developing therapeutics aimed at modulating inflammatory responses. The company operates in both France and the United States, with its lead candidate, obefazimod (ABX464), undergoing crucial clinical trials aimed at treating moderately to severely active ulcerative colitis. Through persistent research and development, Abivax aims to remain at the forefront of innovative treatments that significantly enhance the quality of life for patients suffering from chronic diseases.
Contact Information
For more information, contact:
Patrick Malloy
SVP, Investor Relations Abivax
patrick.malloy@abivax.com
+1 847 987 4878
Frequently Asked Questions
What recent changes occurred in Abivax's Board of Directors?
Abivax announced that Dr. Philippe Pouletty resigned from his position as a director effective December 31, marking a significant transition for the company.
What is the relevance of Dr. Pouletty's resignation?
His resignation is linked to his new appointments as Chairman and CEO of another company, indicating a shift in his professional focus.
What is obefazimod?
Obefazimod is Abivax's lead drug candidate currently in Phase 3 clinical trials aimed at treating ulcerative colitis.
Where does Abivax operate?
Abivax operates in both France and the United States, focusing on inflammatory disease therapeutics.
How does Abivax plan to fill the board vacancy?
Abivax is actively searching for a new board member who can contribute effectively to its development and innovation initiatives.
